{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CRL",
  "name": "Charles River Laboratories International, Inc.",
  "url": "https://orbyd.app/dossiers/CRL/",
  "json_url": "https://orbyd.app/dossiers/CRL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Elliott-driven turnaround at a beaten-down CRO: a ~$295M cost program plus 120–150bps margin expansion is re-rating the stock even with organic revenue still negative (-1.5% Q1), while Q1 proposals up high-single-digits YoY hint DSA bookings are bottoming. The 2026-08-05 Q2 print is the binary gate at ~14x forward EPS this is a probe-not-chase turnaround base, not an accelerating momentum leg.",
  "invalidation_trigger": "A weekly close below $140 loses the 2026 post-activist recovery base and the lowest analyst floor; a secondary break is the 2026-08-05 Q2 print delivering an organic-revenue guide cut, DSA book-to-bill under 1.0, or proposals rolling over.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings 2026-08-05 before open (9:00 a.m. ET call) binary print ~7-8 trading days out; avoid fresh size into it.",
    "Recovery is cost/margin-driven, not demand-driven: organic revenue still negative (-1.5% Q1 2026, FY guide -0.5% to -1.5%); reported top line -5.5% to -4.0% on ~$200M+ divestiture drag.",
    "Leading indicator to watch: Q1 2026 proposals +high-single-digits YoY in both biopharma and biotech needs to convert to DSA bookings on 2026-08-05.",
    "Analyst-target divergence: MS Overweight $260 (2026-07-09) and Mizuho Neutral $230 (2026-07-13) sit above a still-Hold consensus (~$177 avg, range $140-$210) outliers, not base case.",
    "Theme tag corrected from 'precision-biotech-therapeutics' (mislabel — CRL is a CRO, not a therapeutics developer) to CRO/funding-recovery/activist frame.",
    "Watch for a 2026 Investor Day date (TBD) structural re-rate catalyst to reset long-term targets."
  ],
  "body_markdown": "## Current Thesis\nCharles River is the arms dealer to drug development research models, discovery and safety assessment (DSA), and manufacturing solutions sold into pharma and biotech. The tape from 2023–2025 priced it as a structural loser: biotech funding winter gutted preclinical demand, NHP (non-human primate) cost inflation and the DOJ Cambodia-import overhang hit the profit engine, and the stock lost more than half its value. The active narrative now is not growth it is an Elliott-driven turnaround. Since the May 2025 cooperation agreement, the board was refreshed, a Strategic Planning and Capital Allocation Committee stood up, roughly $225M of annualized cost savings plus ~$70M of incremental efficiencies were committed for 2026, and non-core lines (~7% of 2025 revenue) are being divested. The re-rate is being paid for by margins, not demand: FY2026 guidance (reaffirmed 2026-05-07) embeds 120–150 bps of margin expansion, H2-weighted, against organic revenue of -0.5% to -1.5%. What makes it interesting NOW is a leading-indicator inflection Q1 2026 proposals rose high-single-digits YoY in both biopharma and biotech and a sell-side that is starting to warm (MS Overweight, Mizuho PT bump) ahead of a still-Hold consensus. The catch: the whole thing runs into a binary Q2 print on 2026-08-05.\n\n## Bull Case\n- **Proposal inflection precedes bookings.** Q1 2026 (reported 2026-05-07) showed proposals up high-single-digits YoY across both global biopharma and biotech the leading indicator that historically front-runs DSA bookings by one to two quarters. If Q2 confirms bookings following, the demand-recovery leg becomes real rather than hoped-for.\n- **Self-help EPS leverage.** The ~$225M annualized cost program plus ~$70M incremental efficiencies are fully realized in 2026, and guidance carries 120–150 bps of margin expansion weighted to H2. That produces EPS growth on flat-to-negative organic revenue the guide holds non-GAAP EPS at $10.80–$11.30.\n- **Activist catalyst path.** Elliott's May 2025 cooperation agreement, the four new directors, the strategic review, and a 2026 Investor Day (date TBD) to reset long-term targets give a scripted sequence of re-rate events. The 2025-11-05 update and the cell-therapy CDMO closure show the committee is actually cutting, not just studying.\n- **Valuation skew.** At ~$157 (mid-July 2026) on ~$11 forward EPS, the stock trades near 14x well below its historical 20x+ multiple for a franchise CRO. The lowest analyst target sits at $140 (~-11%) against a Street-high $260 (Morgan Stanley, 2026-07-09), an asymmetric payoff if the turnaround converts.\n- **Sell-side beginning to move.** Two PT raises in a week (Morgan Stanley Overweight to $260 on 2026-07-09; Mizuho Neutral to $230 on 2026-07-13) against a consensus still rated Hold the \"before the Street catches up\" window this playbook targets.\n\n## Bear Case\n- **The recovery is cost-driven, not demand-driven.** Organic revenue fell 1.5% in Q1 2026 and FY guidance is -0.5% to -1.5%. DSA the profit engine is still contracting organically. Margin math re-rates a shrinking business only until the cuts are lapped.\n- **The top line optically shrinks all year.** Divestitures cut reported revenue by more than $200M in 2026, dragging reported growth to -5.5% to -4.0%. Headline prints stay red even if the underlying stabilizes.\n- **Margin pressure is not fully cleared.** Q1 margins absorbed NHP cost inflation and CEO-transition stock compensation; the NHP supply and regulatory overhang from the DOJ Cambodia matter has not been fully retired.\n- **Fragile end-demand.** Management flagged that small- and mid-biotech activity \"fluctuated\" by region and business line in Q1. That cohort is the swing factor, and it moves with venture funding, which is not durably back.\n- **Consensus is not convinced.** The stock is rated Hold (roughly 9 hold / 6 buy / 1 sell) with an aggregate target in the high $170s; the $230–$260 prints are the tail, not the base case. If proposals fail to convert to bookings on 2026-08-05, the setup is a value trap at 14x.\n\n## Setup & Price Structure\nPrice sits near $157 (mid-July 2026), mid-range between the lowest analyst target of $140 and the Street-high $260, and well recovered off the 2024–2025 lows. This is a turnaround base consolidating, not an accelerating breakout: organic revenue is still negative and there is no parabolic volume leg to ride. Overhead supply clusters into the high $170s / $180 (the average-target zone); the floor of interest is the post-activist recovery shelf near $140, which doubles as the lowest analyst line in the sand. The two PT raises inside a single week hint at flow warming, but consensus lagging means confirmation still depends on the print. A MATURING turnaround running straight into a binary earnings gate argues for a clean post-print base over chasing the candle the honest stance here is stand aside into 2026-08-05 and let the report set the level, or size only a small probe.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-05 (confirmed):** Q2 2026 earnings, before market open, 9:00 a.m. ET call. The binary. Watch DSA bookings / net book-to-bill, whether Q1's proposal strength converted, the pace of the 120–150 bps margin expansion, and any FY organic-revenue guide revision.\n- **2026, date TBD (est.):** Investor Day to reset long-term financial targets and report strategic-review progress the structural re-rate catalyst; not yet dated inside this 30-day window.\n- **Ongoing:** further divestiture announcements as the non-core (~7% of revenue) disposal program executes; each removes a drag but shrinks reported revenue.\n\n## What Would Change Our Mind\n- A weekly close below $140 loses the 2026 post-activist recovery base and the lowest analyst floor turnaround structure broken, stand aside for a fresh setup.\n- On 2026-08-05: an organic-revenue guide cut, DSA book-to-bill under 1.0, or proposals rolling over invalidates the inflection thesis regardless of where price trades that day.\n- Biotech funding re-freezing (XBI rolling over) removes the demand-recovery leg the bull case leans on.\n- Upside confirmation, not invalidation: a weekly close reclaiming ~$180 on a Q2 that shows DSA bookings inflecting and margins beating would mark the turnaround converting and open the re-rate leg toward the $210–$260 targets.\n\n## Correlation Notes\n- Moves with the CRO / pharma-services complex IQV, ICLR, MEDP, WST, RGEN, BIO where DSA demand is a derivative of biotech venture funding and large-pharma R&D budgets.\n- High beta to biotech risk appetite (XBI, IBB): XBI strength is a tailwind to proposals and bookings; weakness pressures the small/mid-biotech cohort that swings CRL's book.\n- Rate-sensitive through the funding channel easier policy fuels small/mid-biotech spend, which is upstream of preclinical demand.\n- An idiosyncratic activist overlay (Elliott) can decouple CRL from peers on strategic-review, divestiture, or Investor Day headlines, so peer-group beta breaks down around company-specific events.\n\n## Notes\nThis is a turnaround base with a binary print seven-to-eight trading days out, not the accelerating cluster-confirmed momentum leg this book prizes conviction on a fresh entry at ~$157 is a probe at best until 2026-08-05 clears.",
  "first_seen": "2026-07-24",
  "last_analyzed": "2026-07-25T07:09:22+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}